银屑病关节炎远端指间关节滑膜-附着点复合体临床成分与后续对依奇珠单抗或阿达木单抗应答的关联
本事后分析基于SPIRIT-H2H试验(NCT03151551),评估银屑病关节炎患者远端指间关节受累与邻近甲银屑病同时发生的频率,并比较依奇珠单抗(IXE)与阿达木单抗(ADA)对受累指单位的疗效。共354例患者基线时至少1个指单位同时存在远端指间关节受累和邻近甲银屑病,共1309个指单位(IXE组639个,ADA组670个)。IXE组受累指单位完全缓解比例在12周时即显著高于ADA组(38.8% vs 28.4%,P < 0.0001),并持续至52周(64.9% vs 57.5%,P = 0.0055)。
要点
- 银屑病关节炎患者中远端指间关节受累几乎均伴有邻近甲银屑病。
- IXE组受累指单位完全缓解比例12周为38.8%,ADA组为28.4%(P < 0.0001)。
- 52周时IXE组完全缓解比例为64.9%,ADA组为57.5%(P = 0.0055)。
核心结论
- 在该研究队列中,远端指间关节受累的患者几乎均伴有邻近甲银屑病。
- 通过靶向IL-17A的IXE治疗,在52周内所有时间点受累指单位的远端指间关节压痛、肿胀及邻近甲银屑病缓解程度均高于靶向TNF-α的ADA,鉴于既往两类药物肌肉骨骼结局相当,此结果值得注意。
研究设计与样本
- SPIRIT-H2H试验(NCT03151551)的事后分析,比较IXE与ADA治疗银屑病关节炎患者。
- 基线时至少1个指单位同时存在远端指间关节受累(压痛和/或肿胀)和邻近甲银屑病,共354例患者。
- 共1309个指单位(IXE组639个,ADA组670个)基线存在远端指间关节压痛和/或肿胀及邻近甲银屑病,评估至第52周。
主要发现
- 基线时至少1个指单位同时存在远端指间关节受累和邻近甲银屑病的患者共354例。
- 受累指单位完全缓解比例IXE组vs ADA组在12周为38.8% vs 28.4%(P < 0.0001)。
- 受累指单位完全缓解比例IXE组vs ADA组在52周为64.9% vs 57.5%(P = 0.0055),且所有基线后评估至52周均显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the frequency of simultaneous distal interphalangeal (DIP) joint disease and adjacent nail psoriasis (finger unit) among patients with psoriatic arthritis (PsA) and compare the efficacy of the IL-17A antagonist ixekizumab (IXE) and the TNF-α inhibitor adalimumab (ADA). METHODS: This post hoc analysis evaluated the simultaneous occurrence of DIP joint involvement (tenderness and/or swelling) and adjacent nail psoriasis among patients with PsA from the SPIRIT-H2H (NCT03151551) trial comparing IXE to ADA. Among patients with simultaneous DIP joint involvement and adjacent nail psoriasis in ≥1 digit at baseline, treatment effects were assessed through week 52 for each affected finger unit; 'finger unit' defines the connected DIP joint and adjacent nail of an individual digit. RESULTS: A total of 354 patients had simultaneous DIP joint involvement and adjacent nail psoriasis in ≥1 finger unit at baseline. Among them, 1309 (IXE: 639; ADA: 670) finger units had baseline DIP joint tenderness and/or swelling and adjacent nail psoriasis. Proportions of affected finger units achieving complete resolution were significantly higher with IXE vs ADA as early as week 12 (38.8% vs 28.4%, P < 0.0001) and at all post-baseline assessments through week 52 (64.9% vs 57.5%, P = 0.0055). CONCLUSION: In this study cohort, patients with DIP joint involvement almost always had adjacent nail psoriasis. Greater resolution of DIP joint tenderness, swelling and adjacent nail psoriasis was achieved at all time points over 52 weeks through targeting IL-17A with IXE than TNF-α with ADA, which is noteworthy given prior comparable musculoskeletal outcomes for both drug classes.
引用
- McGonagle D, Kavanaugh A, McInnes IB, et al. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford). 2024. PMID: 38341669. doi:10.1093/rheumatology/keae060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。